OIPE
OCT 28 1999
PATENT & TRADEMARK OFFICE
JC84

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	APPLICATION NO.
1581.0300002	09/340,595
APPLICANT: Podhajcer *et al.*	
FILING DATE: June 28, 1999	GROUP: 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
TGL	AA1	5,340,934	08/23/1994	Termine *et al.*	536	23.5	11/03/1989

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
TGL	AL1	WO 96/26267	08/29/1996	WIPO	—	—	Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

TGL	AR	1	Aoki, K., *et al.*, "Liposome-mediated *in Vivo* Gene Transfer of Antisense K-*ras* Construct Inhibits Pancreatic Tumor Dissemination in the Murine Peritoneal Cavity," *Cancer Res.* *55*:3810-3816 (September 1995)
TGL	AS	1	Bellahcène, A., and Castronovo, V., "Increased Expression of Osteonectin and Osteopontin, Two Bone Matrix Proteins, in Human Breast Cancer," *Amer. J. Pathol.* *146*:95-100 (January 1995)
TGL	AT	1	Collier, I.E., *et al.*, "H-ras Oncogene-transformed Human Bronchial Epithelial Cells (TBE-1) Secrete a Single Metalloprotease Capable of Degrading Basement Membrane Collagen," *J. Biol. Chem.* *263*:6579-6587 (May 1988)

EXAMINER: Thomas G. Tarn — DATE CONSIDERED: 12/19/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE JC84
OCT 2 8 1999
PATENT & TRADEMARK OFFICE

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1581.0300002	APPLICATION NO. 09/340,595
	APPLICANT Podhajcer *et al.*	
	FILING DATE June 28, 1999	GROUP 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

DL	AR	2	Everitt, E.A., and Sage, E.H., "Expression of SPARC is Correlated with Altered Morphologies in Transfected F9 Embryonal Carcinoma Cells," *Exp. Cell Res. 199*:134-146 (1992)
DL	AS	2	Everitt, E.A., and Sage, E.H., "Overexpression of SPARC in stably transfected F9 cells mediates attachment and spreading in Ca^{2+}-deficient medium," *Biochem. Cell Biol. 70*:1368-1379 (December 1992)
DL	AT	2	Funk, S.E., and Sage, E.H., "The Ca^{2+}-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells," *Proc. Natl. Acad. Sci. USA 88*:2648-2652 (April 1991)

EXAMINER Thomas D. Lazar — DATE CONSIDERED 12/19/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE
OCT 28 1999
PATENT & TRADEMARK OFFICE

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1581.0300002	APPLICATION NO. 09/340,595
	APPLICANT Podhajcer *et al.*	
	FILING DATE June 28, 1999	GROUP 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

TH	AR	3	Funk, S.E., and Sage, E.H., "Differential effects of SPARC and Cationic SPARC Peptides on DNA Synthesis by Endothelial Cells and Fibroblasts," *J. Cell. Physiol. 154*:53-63 (Jan. 1993)
TH	AS	3	Harlow, E., and Lane, D., "Chapter 5: Immunizations," in *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 53-137 (1988)
TH	AT	3	Kamihagi, K., *et al.*, "Osteonectin/SPARC Regulates Cellular Secretion Rates of Fibronectin and Laminin Extracellular Matrix Proteins," *Biochem. Biophys. Res. Comm. 200*:423-428 (April 1994)

EXAMINER Thomas G. Tate DATE CONSIDERED 12/9/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE
OCT 28 1999
PATENT & TRADEMARK OFFICE

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1581.0300002	APPLICATION NO. 09/340,595
	APPLICANT Podhajcer *et al.*	
	FILING DATE June 28, 1999	GROUP 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

TGL	AR	4	Laird, A.D., *et al.*, "Inhibition of Tumor Growth in Liver Epithelial Cells Transfected with a Transforming Growth Factor α Antisense Gene," *Cancer Res.* *54*:4224-4232 (August 1994)
TGL	AS	4	Lane, T.F., and Sage, E.H., "Functional Mapping of SPARC: Peptides from Two Distinct Ca^{++}-binding Sites Modulate Cell Shape," *J. Cell Biol.* *111*:3065-3076 (December 1990)
TGL	AT	4	Lane, T.F., *et al.*, "Regulation of Gene Expression by SPARC during Angiogenesis *in Vitro*," *J. Biol. Chem.* *267*:16736-16745 (August 1992)

EXAMINER Thomas G. Gass — DATE CONSIDERED 12/19/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE
OCT 2 8 1999
PATENT & TRADEMARK OFFICE

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1581.0300002	APPLICATION NO. 09/340,595
	APPLICANT Podhajcer *et al.*	
	FILING DATE June 28, 1999	GROUP 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

VGL	AR	5	Lane, T.F., and Sage, E.H., "The biology of SPARC, a protein that modulates cell-matrix interactions," *FASEB J.* *8*:163-173 (February 1994)
VGL	AS	5	Lane, T.F., *et al.*, "SPARC Is a Source of Copper-binding Peptides that Stimulate Angiogenesis," *J. Cell Biol.* *125*:929-943 (May 1994)
VGL	AT	5	Ledda, M.F., *et al.*, "Expression of SPARC in melanoma and dysplastic nevi," *Proceedings of the American Association for Cancer Research Annual Meeting* *36*:63 (1995)

EXAMINER Thomas G. Larson DATE CONSIDERED 12/19/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIP
OCT 28 1999
PATENT & TRADEMARK OFFICE

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1581.0300002	APPLICATION NO. 09/340,595
	APPLICANT Podhajcer *et al.*	
	FILING DATE June 28, 1999	GROUP 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

TDL	AR	6	Ledda, M.F., *et al.*, "Rol del Gen SPARC en la Capacidad Tumorigenica de Celulas de Melanoma Humano," *Medicina (Buenos Aires) 56*:51-54 (1996)(English translation attached - Ledda, M.F., *et al.*, "The role of SPARC gene in the tumorigenic capacity of human melanoma cells")
TDL	AS	6	Ledda, F., *et al.*, "The Expression of the Secreted Protein Acidic and Rich in Cysteine (SPARC) Is Associated with the Neoplastic Progression of Human Melanoma," *J. Invest. Dermatol. 108*:210-214 (February 1997)
TDL	AT	6	Ledda, M.F., *et al.*, "Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells," *Nature Med. 3*:171-176 (February 1997)

EXAMINER Thomas G. Jarmon — DATE CONSIDERED 12/19/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE
OCT 28 1999
PATENT & TRADEMARK OFFICE
JC84

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1581.0300002	APPLICATION NO. 09/340,595
	APPLICANT Podhajcer *et al.*	
	FILING DATE June 28, 1999	GROUP 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

TH	AR	7	Mason, I.J., *et al.*, "Evidence from molecular cloning that SPARC, a major product of the mouse embryo parietal endoderm, is related to an endothelial cell 'culture shock' glycoprotein of M_r 43 000," *EMBO J.* 5:1465-1472 (July 1986)
TH	AS	7	Maurer, P., *et al.*, "High-affinity and low-affinity calcium binding and stability of the multidomain extracellular 40-kDa basement membrane glycoprotein (BM-40/SPARC/osteonectin)," *Eur. J. Biochem.* 205:233-240 (April 1992)
TH	AT	7	Mercola, D., and Cohen, J.S., "Antisense approaches to cancer gene therapy," *Cancer Gene Ther.* 2:47-59 (March 1995)

EXAMINER Thomas G. Gram DATE CONSIDERED 12/19/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE
OCT 2 8 [illegible]
PATENT & TRADEMARK OFFICE

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1581.0300002	APPLICATION NO. 09/340,595
	APPLICANT Podhajcer *et al.*	
	FILING DATE June 28, 1999	GROUP 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

[signature]	AR	8	Mok, S.C., *et al.*, "SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells," *Oncogene 12*:1895-1901 (May 1996)
[signature]	AS	8	Podhajcer, O.L., *et al.*, "Comparative expression of the SPARC and stromelysin-3 genes in mammary tumours," *The Breast 5*:13-20 (February 1996)
[signature]	AT	8	Podhajcer, O.L., *et al.*, "Expression of Cathepsin D in Primary and Metastatic Human Melanoma and Dysplastic Nevi," *J. Invest. Dermatol. 104*:340-344 (March 1995)

EXAMINER [signature]	DATE CONSIDERED 12/19/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE
OCT 28 1999
PATENT & TRADEMARK OFFICE

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1581.0300002	APPLICATION NO. 09/340,595
	APPLICANT Podhajcer *et al.*	
	FILING DATE June 28, 1999	GROUP 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

TDL	AR	9	Porte, H., *et al.*, "Neoplastic Progression of Human Colorectal Cancer is Associated with Overexpression of the Stromelysin-3 and *BM-40/SPARC* Genes," *Int. J. Cancer. 64*:70-75 (February 1995)
TDL	AS	9	Porter, P.L., *et al.*, "Distribution of SPARC in Normal and Neoplastic Human Tissue," *J. Histochem. Cytochem. 43*:791-800 (August 1995)
TDL	AT	9	Pottgiesser, J., *et al.*, "Changes in Calcium and Collagen IV Binding Caused by Mutations in the EF Hand and Other Domains of Extracellular Matrix Protein BM-40 (SPARC, Osteonectin)," *J. Mol. Biol. 238*:563-574 (May 1994)

EXAMINER Thomas G. Jones	DATE CONSIDERED 12/19/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE
OCT 28 1999
PATENT & TRADEMARK OFFICE

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1581.0300002	APPLICATION NO. 09/340,595
	APPLICANT Podhajcer *et al.*	
	FILING DATE June 28, 1999	GROUP 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

DH	AR	10	Sage, H., *et al.*, "SPARC, A Secreted Protein Associated with Cellular Proliferation, Inhibits Cell Spreading In Vitro and Exhibits Ca^{+2}-dependent Binding to the Extracellular Matrix," *J. Cell Biol. 109*:341-356 (July 1989)
DH	AS	10	Sage, E.H., and Bornstein, P., "Extracellular Proteins That Modulate Cell-Matrix Interactions," *J. Biol. Chem. 266*:14831-14834 (August 1991)
DH	AT	10	Sage, E.H., "Terms of attachment: SPARC and tumorigenesis," *Nature Med. 3*:144-146 (February 1997)

EXAMINER Thomas G. Larson	DATE CONSIDERED 12/19/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE
OCT 2 8 1999
PATENT & TRADEMARK OFFICE

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1581.0300002	APPLICATION NO. 09/340,595
	APPLICANT Podhajcer *et al.*	
	FILING DATE June 28, 1999	GROUP 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

TBL	AR	11	Swaroop, A., *et al.*, "Molecular Analysis of the cDNA for Human SPARC/Osteonectin/BM-40: Sequence, Expression and Localization of the Gene to Chromosome 5q31-q33," *Genomics 2*:37-47 (January 1988)
TBL	AS	11	Tremble, P.M., *et al.*, "SPARC, a Secreted Protein Associated with Morphogenesis and Tissue Remodeling, Induces Expression of Metalloproteinases in Fibroblasts Through a Novel Extracellular Matrix-dependent Pathway," *J. Cell Biol. 121*:1433-1444 (June 1993)
TBL	AT	11	Trojan, J., *et al.*, "Treatment and Prevention of Rat Glioblastoma by Immunogenic C6 Cells Expressing Antisense Insulin-Like Growth Factor I RNA," *Science 259*:94-97 (January 1993)

EXAMINER Thomas G. Larson DATE CONSIDERED 12/19/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

P:\USERS\DTWEI\1581\0300002\IDS1449

OIPE JC84
OCT 2 8 1999
PATENT & TRADEMARK OFFICE

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1581.0300002	APPLICATION NO. 09/340,595
	APPLICANT Podhajcer *et al.*	
	FILING DATE June 28, 1999	GROUP 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

DM	AR	12	International Search Report for PCT/GB97/03548, mailed July 16, 1998
	AS	12	

EXAMINER Thomas G. Larson DATE CONSIDERED 12/19/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

P:\USERS\DTWEI\1581\0300002\IDS1449